23 results
FWP
ACXP
Acurx Pharmaceuticals, Inc.
2 Apr 24
Free writing prospectus
7:31am
- on: community - acquired bacterial pneumonia, hospital and/or ventilator - associated bacterial pneumonia; bacteremia with or w/o infectious
8-K
EX-99.1
ACXP
Acurx Pharmaceuticals, Inc.
14 Nov 23
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2023 Results and Provides Business Update
4:05pm
(SHEA), CDI remains a significant medical problem in hospitals, in long term care facilities and in the community. C. difficile is one of the most
8-K
EX-99.1
cvge0um60up
3 Nov 23
Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection
4:05pm
8-K
EX-99.1
asfja4 j5qhprd
2 Oct 23
Other Events
4:41pm
8-K
EX-99.1
w5stw1h 4ugddu
14 Aug 23
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2023 Results and Provides Business Update
7:10am
10-K
ukzhm428q16gsltfapoo
16 Mar 22
Annual report
4:05pm
10-Q
4lfb y9h38hi
13 Aug 21
Quarterly report
4:06pm
S-8
EX-99.3
3c40 yuzo1ie5
19 Jul 21
Registration of securities for employees
5:27pm
424B4
po5juvul
28 Jun 21
Prospectus supplement with pricing info
6:02am
S-1/A
v5e9oh7vktjzkdf93
11 Jun 21
IPO registration (amended)
6:02am